Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02279433 · ClinicalTrials.gov registry record · Phase 1

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

A Phase 1 study of Solid Tumors, sponsored by Nuvation Bio.

Completed
Registry status
Phase 1
Development phase
46
Enrollment target
6
Study locations

NCT02279433: Completed Phase 1 study of Solid Tumors, sponsored by Nuvation Bio.

NCT02279433 is a Phase 1 study of Solid Tumors that has completed, run by Nuvation Bio. The registered enrollment target is 46 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02279433, a Phase 1 study of Solid Tumors, has completed, sponsored by Nuvation Bio.

COMPLETED
Registry status
Phase 1
Development phase
46 participants
Enrollment target
6
Study locations

Study Summary

DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.

Conditions Studied

Solid Tumors

Interventions

  • DRUG DS6051b

Study Locations (6)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Inst. - Boston

Arizona

  • HonorHealth Research Institute - Scottsdale

California

  • Chao Family Comprehensive Cancer Center of - Orange

New York

  • New York University - New York

Texas

  • South Texas Accelerated Research Therapeutics - San Antonio

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2014-09
Est. Completion 2019-03
Phase Phase 1
Nuvation Bio

7 total trials

What the finished NCT02279433 record still lists

NCT02279433 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which DS6051b is the first listed.

NCT02279433 lists 6 locations in 5 states (Massachusetts, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT02279433 about?

NCT02279433 is a clinical study titled "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b". DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study wil...

What is the current status of trial NCT02279433?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2014-09. Estimated completion is 2019-03.

What conditions does trial NCT02279433 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT02279433?

The interventions under investigation include: DS6051b (DRUG).

Who is sponsoring clinical trial NCT02279433?

This trial is sponsored by Nuvation Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02279433 being conducted?

This trial has 6 study locations across Arizona, California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02279433's enrollment target sits among peer trials

46 84th of 125 higher than 41 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02279433, the US trial registry maintained by the National Library of Medicine. NCT02279433 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.